Finanzas de Assembly Biosciences Inc (ASMB)ASMBAssembly Biosciences Inc

Evaluating the bottom line, Assembly Biosciences Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -47.44%, while the net margin is -28.84%. These profitability ratios, combined with a Return on Equity (ROE) of -0.03%, provide a clear picture of how effectively ASMB converts its operational activities into shareholder value.

In the context of the broader market, ASMB competes directly with industry leaders such as SPRY and AUTL. With a market capitalization of $409.04M, it holds a significant position in the sector. When comparing efficiency, ASMB's gross margin of 100.00% stands against SPRY's 61.83% and AUTL's 57.61%. Such benchmarking helps identify whether Assembly Biosciences Inc is trading at a premium or discount relative to its financial performance.

The company has shown fluctuating revenue with a significant increase in Q4 2025 to $42,469,000, but has reported net losses in several quarters, including a loss of $3,857,000 in Q2 2026. Gross margins remain strong at 100%, but net margins are negative, indicating ongoing financial challenges.